无细胞DNA用于检测脏异种移植排斥
Olivier Aubert1,2, Cindy Ursule-Dufait1, Romain Brousse1
1Université Paris Cité, INSERM U970, Paris Institute for Transplantation and Organ Regeneration, Paris, France.
Nature medicine
|June 2, 2024
概括
捐赠者衍生的无细胞DNA (dd-cfDNA) 与脏全移植排斥有很强的相关性,包括抗体介导和T细胞介导的类型. 这种非侵入性生物标志物改善了超越标准监测的检测,为移植受体提供了重要的临床价值.
科学领域:
- 移植免疫学 移植免疫学
- 发现生物标志物的发现.
- 非侵入性诊断是一种非侵入性诊断.
背景情况:
- 捐赠者衍生的无细胞DNA (dd-cfDNA) 是一个有前途的非侵入性生物标志物,用于检测异种移植损伤.
- 在移植中,dd-cfDNA的临床实用性,特别是其与标准监测相比的附加值,需要进一步研究.
研究的目的:
- 评估dd-cfDNA检测移植异位排斥的能力.
- 评估dd-cfDNA在标准患者监测参数之外的临床附加值.
主要方法:
- 一项基于人口的观察性研究,在14个中心招募了2882名移植患者.
- 主要分析包括1,134名患者,对1,748名患者进行了外部验证,其中包括一组非裔美国患者.
- 多变量分析和预测模型被用来评估dd-cfDNA与排斥的关联及其对诊断性能的影响.
主要成果:
- dd-cfDNA水平与异位移植排斥有很强的相关性,包括抗体介导,T细胞介导和混合排斥 (P < 0.0001).
- 循环的dd-cfDNA与标准监测 (OR 2.275;P < 0.0001) 独立于异位移植排斥有显著的相关性.
- 包括dd-cfDNA改进了预测模型的歧视 (AUC 0.777到0.821;P = 0.0011) 和校准,在验证队列中得到确认的结果.
结论:
- dd-cfDNA是一种有价值的非侵入性生物标志物,用于检测移植异位排斥.
- 将dd-cfDNA纳入监测策略可以提高拒绝的检测,包括稳定患者的亚临床形式.
- 这些发现支持对dd-cfDNA的评估与标准护理一起,以改善全移植监测.
相关概念视频
Kidney Transplant I: Introduction
827
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
827
Kidney Transplant II: Surgical Procedure
926
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
926


